GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE317nnn/GSE317101/primaryOK200TranscriptomicsHomo sapiens OtherExpression profiling by high throughput sequencinghttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317101GEOGSEfalseA hematopoietic stem cell shield for AML-directed immunotherapyOne major challenge in the development of successful chimeric antigen receptor (CAR) T cells for patients with acute myeloid leukemia (AML) has been that most well-studied AML-associated antigens are also expressed on vital normal hematopoietic stem cells (HSCs) or mature myeloid cells. This challenge in optimal antigen selection leads to deleterious on-target toxicity, particularly in the context of CAR T cell persistence. CAR T cells targeting CD371, a type II transmembrane glycoprotein, have shown potent anti-leukemic activity in phase I trials to date; however, CD371 is wildly expressed throughout the normal myeloid compartment. Here we identify that CD371 is dispensable for normal human HSC and myeloid cell function, map the epitope of a CD371 CAR T cell currently in phase I trials, develop a base-editing strategy to shield normal hematopoiesis from CD371-directed immunotherapy, and describe an off-the-shelf approach to target AML while sparing normal hematopoiesis through the use of CD371 CAR T cells.2026/04/08GSE317101GSM9465239GSM9465238GSM9465240GSM9465242GSM9465241GSM946524324676317101Homo sapiens